BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 23994370)

  • 1. Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder.
    Xylinas E; Cha EK; Khani F; Kluth LA; Rieken M; Volkmer BG; Hautmann R; Küfer R; Chen YT; Zerbib M; Rubin MA; Scherr DS; Shariat SF; Robinson BD
    J Urol; 2014 Mar; 191(3):830-41. PubMed ID: 23994370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder.
    Patschan O; Shariat SF; Chade DC; Karakiewicz PI; Ashfaq R; Lotan Y; Hotakainen K; Stenman UH; Bjartell A
    World J Urol; 2012 Dec; 30(6):785-94. PubMed ID: 21739120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy.
    da Silva RD; Xylinas E; Kluth L; Crivelli JJ; Chrystal J; Chade D; Guglielmetti GB; Pycha A; Lotan Y; Karakiewicz PI; Sun M; Fajkovic H; Zerbib M; Scherr DS; Shariat SF
    J Urol; 2013 Aug; 190(2):487-92. PubMed ID: 23395802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder.
    Sitnikova L; Mendese G; Liu Q; Woda BA; Lu D; Dresser K; Mohanty S; Rock KL; Jiang Z
    Clin Cancer Res; 2008 Mar; 14(6):1701-6. PubMed ID: 18347170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IMP3 expression in urothelial carcinomas of the urinary bladder.
    Ozdemir NO; Türk NS; Düzcan E
    Turk Patoloji Derg; 2011 Jan; 27(1):31-7. PubMed ID: 21469424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy.
    Rink M; Park K; Volkmer BG; Xylinas E; Hansen J; Cha EK; Robinson BD; Hautmann R; Küfer R; Engel O; Chun FK; Dahlem R; Rubin MA; Shariat SF; Mosquera JM
    Urol Oncol; 2013 Nov; 31(8):1716-24. PubMed ID: 22944196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor messenger RNA-binding protein 3 expression helps prognostication in patients with upper tract urothelial carcinoma.
    Lee DJ; Xylinas E; Rieken M; Khani F; Klatte T; Wood CG; Karam JA; Weizer AZ; Raman JD; Remzi M; Guo CC; Rioux-Leclercq N; Haitel A; Bolenz C; Bensalah K; Sagalowsky AI; Montorsi F; Lotan Y; Shariat SF; Robinson BD; Margulis V
    Eur Urol; 2014 Aug; 66(2):379-85. PubMed ID: 24388440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.
    Karam JA; Shariat SF; Huang HY; Pong RC; Ashfaq R; Shapiro E; Lotan Y; Sagalowsky AI; Wu XR; Hsieh JT
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4400-6. PubMed ID: 17671122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Tumor Diameter and Tumor Necrosis on Oncologic Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.
    Soave A; John LM; Dahlem R; Minner S; Engel O; Schmidt S; Kluth LA; Fisch M; Rink M
    Urology; 2015 Jul; 86(1):92-8. PubMed ID: 26051839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness.
    Wittschieber D; Stenzinger A; Klauschen F; Stephan C; Jung K; Erbersdobler A; Rabien A
    Pathobiology; 2011; 78(3):123-31. PubMed ID: 21613799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma.
    Rieken M; Xylinas E; Kluth L; Crivelli JJ; Chrystal J; Faison T; Lotan Y; Karakiewicz PI; Sun M; Fajkovic H; Babjuk M; Bachmann A; Scherr DS; Shariat SF
    Urol Oncol; 2014 Jan; 32(1):49.e7-14. PubMed ID: 24140245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IMP3 is a biomarker for non-muscle-invasive urothelial carcinoma of the bladder associated with an aggressive phenotype.
    Yang F; Zhou Q; Meng L; Xing N
    Medicine (Baltimore); 2019 Jul; 98(27):e16009. PubMed ID: 31277094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes.
    Ma B; Li H; Zhang C; Yang K; Qiao B; Zhang Z; Xu Y
    Eur J Surg Oncol; 2013 Oct; 39(10):1150-6. PubMed ID: 23721764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.
    de Jong JJ; Stoop H; Nieboer D; Boormans JL; van Leenders GJLH
    Histopathology; 2018 Dec; 73(6):983-989. PubMed ID: 30003574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urachal Carcinoma of the Bladder: Impact of Clinical and Immunohistochemical Parameters on Prognosis.
    Niedworok C; Panitz M; Szarvas T; Reis H; Reis AC; Szendröi A; Nyirády P; Szasz AM; Módos O; Rübben H; Vom Dorp F
    J Urol; 2016 Jun; 195(6):1690-6. PubMed ID: 26678957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of body mass index on the oncological outcomes of patients treated with radical cystectomy for muscle-invasive bladder cancer.
    Dabi Y; Rouscoff Y; Anract J; Delongchamps NB; Sibony M; Saighi D; Zerbib M; Peyraumore M; Xylinas E
    World J Urol; 2017 Feb; 35(2):229-235. PubMed ID: 27272203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
    Shariat SF; Karakiewicz PI; Palapattu GS; Lotan Y; Rogers CG; Amiel GE; Vazina A; Gupta A; Bastian PJ; Sagalowsky AI; Schoenberg MP; Lerner SP
    J Urol; 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422. PubMed ID: 17085118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients.
    Tilki D; Svatek RS; Karakiewicz PI; Isbarn H; Reich O; Kassouf W; Fradet Y; Novara G; Fritsche HM; Bastian PJ; Izawa JI; Stief CG; Ficarra V; Lerner SP; Schoenberg M; Dinney CP; Skinner E; Lotan Y; Sagalowsky AI; Shariat SF
    J Urol; 2010 Jan; 183(1):87-93. PubMed ID: 19942232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes after urothelial recurrence in bladder cancer patients undergoing radical cystectomy.
    Mitra AP; Alemozaffar M; Harris BN; Schuckman AK; Skinner EC; Daneshmand S
    Urology; 2014 Dec; 84(6):1420-6. PubMed ID: 25306479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.